C14 Ceramide (d18:1/14:0) (Synonyms: Cer(d18:1/14:0)) |
Catalog No.GC43022
One-Click Copy Product Info
|
C14 Ceramide (d18:1/14:0) is an endogenous sphingolipid molecule produced by ceramide synthase 6.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 34227-72-0
Sample solution is provided at 25 µL, 10mM.
C14 Ceramide (d18:1/14:0) is an endogenous sphingolipid molecule produced by ceramide synthase 6. C14 Ceramide participates in the regulation of biological processes such as cell proliferation, differentiation, and apoptosis. C14 Ceramide can be used in research related to Parkinson's disease, diabetes, cystic fibrosis, and hepatic steatosis[1-4].
In vitro, MDA435/LCC6 human breast cancer cells and J774 mouse macrophage cells were treated with C14 Ceramide (0-100μM) for 72 hours. C14 Ceramide (greater than 1μM) inhibited cell viability but exhibited low cytotoxicity (IC50>100μM)[5].
References:
[1] Xing, Y., Tang, Y., Zhao, L., et al. Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson’s disease dementia. J. Neurol. Sci. 2016. 370, 82-87.
[2] Oertel S, Scholich K, Weigert A, et al. Ceramide synthase 2 deficiency aggravates AOM-DSS-induced colitis in mice: role of colon barrier integrity. Cell Mol Life Sci. 2017 Aug;74(16):3039-3055.
[3] Choi S, Snider JM, Olakkengil N, et al. Myristate-induced endoplasmic reticulum stress requires ceramide synthases 5/6 and generation of C14-ceramide in intestinal epithelial cells. FASEB J. 2018 Oct;32(10):5724-5736.
[4] Lin H, Ma C, Cai K, et al. Metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis. Science. 2025 May;388(6746):eado4188.
[5] Shabbits JA, Mayer LD. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta. 2003 May 2;1612(1):98-106.
| Cell experiment [1]: | |
Cell lines | MDA435/LCC6 human breast cancer cells and J774 mouse macrophage cells |
Preparation Method | Cells were grown as adherent monolayer cultures in DMEM supplemented with 10% fetal bovine serum and 1% L-glutamine, maintained at 37°C in humidified air with 5% CO₂. Cells were seeded into 96-well microtiter plates and allowed to adhere for 24 hours, then treated with C14 Ceramide at concentrations ranging from 0-100μM for 72 hours. |
Reaction Conditions | 0-100μM; 72 hours |
Applications | C14 Ceramide showed low cytotoxicity (IC50>100μM) in both MDA435/LCC6 human breast cancer cells and J774 mouse macrophage cells. The cytotoxic activity of ceramides was inversely proportional to acyl chain length, with C14 Ceramide being less active than shorter chain ceramides. |
References: | |
| Cas No. | 34227-72-0 | SDF | |
| Synonyms | Cer(d18:1/14:0) | ||
| Chemical Name | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-tetradecanamide | ||
| Canonical SMILES | OC[C@H](NC(CCCCCCCCCCCCC)=O)[C@H](O)/C=C/CCCCCCCCCCCCC | ||
| Formula | C32H63NO3 | M.Wt | 509.9 |
| Solubility | DMF: 0.15 mg/mL | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9612 mL | 9.8058 mL | 19.6117 mL |
| 5 mM | 392.2 μL | 1.9612 mL | 3.9223 mL |
| 10 mM | 196.1 μL | 980.6 μL | 1.9612 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >97.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)